Efficacy of Leu-Ile-Lys tripeptide in the correction of experimental urate nephrolithiasis

Abstract

Aim. To study the effect of the Leu-Ile-Lys (leucine-isoleucine-lysine) tripeptide on the course of experimental urate nephrolithiasis.

Methods. The experiment was carried out on 23 male Wistar rats weighing 200–220 grams that were divided into a control (n=8, modeling of urate nephrolithiasis) and an experimental (n=15, modeling of urate nephrolithiasis + ¬administration of Leu-Ile-Lys tripeptide) groups. The tripeptide was administered intragastrically through a tube at a dose of 11.5 mg/kg. Daily urine was collected on a weekly basis, and the activity of lactate dehydrogenase and gamma-glutamyl transpeptidase was determined. After three weeks of the experiment, the animals were euthanized, and kidneys were removed to determine the parameters of free radical oxidation [concentration of thiobarbituric acid reactive substances (TARS), total pro-oxidant and total antioxidant activity, the activities of catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (GPX)] and conduct a morphological study in which the number and area of calculi and the condition of the renal tissues were determined. Statistical data processing was performed using the Statistica 12.0 software. We used the Mann–Whitney U test, the Wilcoxon signed rank test. The results are presented as median with the 25th and 75th percentiles. The differences were considered significant at p <0.05.

Results. In the kidneys of the rats of the experimental group, the number of deposits decreased twofold, as compared with the control group (1.6±0.2 and 3.2±0.4, respectively, p=0.001). Lactate dehydrogenase activity in the urine of rats increased from 0.10 (0.06; 0.21) units/mg of creatinine per day initially to 0.75 (0.44; 1.07) units/mg creatinine per day on day 21 (p=0.012) in the control group, and from 0.10 (0.06; 0.12) units/mg creatinine per day to 0.45 (0.34; 0.71) units/mg creatinine per day on 21st day (p=0.003) in the experimental group. The concentration of thiobarbituric acid reactive substances in the experimental group was 1.2 times lower than that of the control group: 4.2 (3.9; 4.6) μmol and 5.1 (4.7; 5.5) μmol, respectively (p <0.001). In addition, in the kidneys of the rats of the experimental group, the total antioxidant activity was 1.3 times higher than in control: 70.4 (65.4; 74.1)% and 53.8 (33.3; 62.2)% respectively (p <0.001). Superoxide dismutase activity in the experimental group was 1.5 times higher than in the control group: 12.4 (11.0; 13.2)% against 8.1 (6.4; 13.1)% (p=0.016). Catalase activity in the experimental group was 1.2 times higher than in the control group: 31.1 (26.4; 36.1)% against 25.1 (20.3; 27.1)% (p=0.005).

Conclusion. The Leu-Ile-Lys tripeptide has a litholytic effect, manifested in a statistically significant decrease in the activity of oxidative stress markers (p <0,001) and a twofold decrease in the average amount of uric acid kidney stones (p <0,001).

Keywords

urate nephrolithiasis / Leu-Ile-Lys tripeptide / pharmacological correction

References

[1] Sakhaee K. Epidemiology and clinical pathophysio­logy of uric acid kidney stones. J. Nephrol. 2014; 27: 241–245. DOI: 10.1007/s40620-013-0034-z.

[2] Ferraro P.M., Gambaro G. Calcolosi uratica. Giornale Italiano Di Nefrologia. 2015; 32: 62. (In Italian). PMID: 26005875.

[3] Spatola L., Ferraro P.M., Gambaro G., Badalamenti S., Dauriz M. Metabolic syndrome and uric acid nephrolithiasis: insulin resistance in focus. Metabolism. 2018; 83: 225–233. DOI: 10.1016/j.metabol.2018.02.008.

[4] Klinicheskie rekomendacii. Mochekamennaya bolezn'. 2020. (Clinical guidelines “Urolithiasis”. 2020.) (01.06.2020). https://clck.ru/SiEx4 (access date: 29.03.2021). (In Russ.)

[5] Клинические рекомендации. Мочекаменная болезнь. 2020 (01.06.2020). Утверждены Минздравом РФ. https://clck.ru/SiEx4 (дата обращения: 29.03.2021).

[6] Alyaev Yu.G., Rudenko V.I. Modern aspects of drug treatment of patients with kidney stone disease. Effektivnaya farmakoterapiya. Urologiya i nefrologiiya. 2016; (5): 23–27. (In Russ.)

[7] Аляев Ю.Г., Руденко В.И. Современные аспекты медикаментозного лечения пациентов с мочекаменной болезнью. Эффектив. фармакотерап. Урология и нефрология. 2016; (5): 23–27.

[8] Zharikov A.Y., Yakushev N.N., Zharikova G.V., Mazko O.N., Makarova O.G., Lepilov A.V., Bobrov I.P. Effect of tripeptide leu-ile-lys on the course of experimental nephrolithiasis. Bulletin of experimental biology and medicine. 2019; 167 (6): 747–750. (In Russ.) DOI: 10.1007/s10517-019-04614-w.

[9] Жариков А.Ю., Якушев Н.Н., Жарикова Г.В., Мазко О.Н., Макарова О.Г., Лепилов А.В., Бобров И.П. Влияние трипептида Leu-Ile-Lys на течение экспериментального оксалатного нефролитиаза. Бюлл. эксперим. биол. и мед. 2019; 167 (6): 704–708. DOI: 10.1007/s10517-019-04614-w.

[10] Zharikov A.Y., Yakushev N.N., Mazko O.N., Makarova O.G., Lepilov A.V., Bobrov I.P., Zharikova G.V., Kiselev V.I. Experience of ­using Leu-Ile-Lys tripeptide for experimental therapy of chronic 16-week oxalate nephrolithiasis in rats. Bulletin of experimental biology and me­dicine. 2020; 169 (2): 237–241. (In Russ.) DOI: 10.1007/s10517-020-04858-x.

[11] Жариков А.Ю., Якушев Н.Н., Мазко О.Н., Макарова О.Г., Лепилов А.В., Бобров И.П., Жарикова Г.В., Киселёв В.И. Опыт применения трипептида Leu-Ile-Lys для экспериментальной терапии хронического 16-­недельного оксалатного нефролитиаза у крыс. Бюлл. эксперим. биол. и мед. 2020; 169 (2): 197–202. DOI: 10.1007/s10517-020-04858-x.

[12] Perfilev V.Yu., Zverev Ya.F., Zharikov A.Yu. Сonditions of urate nephrolithiasis and approaches to its modeling. Nefrologiya. 2017; 21 (4): 48–54. (In Russ.) DOI: 10.24884/1561-6274-2017-21-4-48-54.

[13] Перфильев В.Ю., Зверев Я.Ф., Жариков А.Ю. Условия развития уратного нефролитиаза и подходы к его моделированию. Нефрология. 2017; 21 (4): 48–54. DOI: 10.24884/1561-6274-2017-21-4-48-54.

[14] Kabakov A.E., Gabai V.L. Cell deathand survi­val assays. Methods Mol. Biol. 2018; 1709: 107–127. DOI: 10.1007/978-1-4939-7477-1_9.

[15] Kalnitsky A.S., Zharikov A.Yu., Mazko O.N., Makarova O.G., Bobrov I.P., Azarova O.V. Effect of carnosine on the course of experimental urate nephrolithiasis. Byulleten' eksperimental'noy biologii i meditsiny. 2021; 171 (2): 182–185. (In Russ.) DOI: 10.47056/0365-9615-2021-171-2-182-185.

[16] Кальницкий А.С., Жариков А.Ю., Мазко О.Н., Макарова О.Г., Бобров И.П., Азарова О.В. Влияние карнозина на течение экспериментального уратного нефролитиаза. Бюлл. эксперим. биол. и мед. 2021; 171 (2): 182–185. DOI: 10.47056/0365-9615-2021-171-2-182-185.

[17] Bryukhanov V.M., Zverev Ya.F., Lampatov V.V., Zharikov A.Yu., Talalaeva O.S. Metody doklinicheskogo (ehksperimentalʹnogo) issledovaniya vliyaniya lekarstvennykh sredstv na funktsiy upochek. (Methods of preclinical (experimental) study of the effect of drugs on renal function.) Novosibirsk: Geo. 2013; 84 р. (In Russ.)

[18] Брюханов В.М., Зверев Я.Ф., Лампатов В.В., Жариков А.Ю., Талалаева О.С. Методы доклинического (экспериментального) исследования влияния лекарственных средств на функцию почек. Новосибирск; Гео. 2013; 84 с.

[19] Khafizyanova R.Kh., Burikin I.M., Aleeva G.N. Matematicheskaya statistika v eksperimental'noy i klini­cheskoy farmakologii. (Mathematical statistics in experimental and clinical pharmacology.) Kazan: Meditsina. 2006: 374 p. (In Russ.)

[20] Хафизьянова Р.Х., Бурыкин И.М., Алеева Г.Н. Математическая статистика в экспериментальной и клинической фармакологии. Казань: Медицина. 2006: 374 c.

[21] Khan S.R. Stress oxidative: nephrolithiasis and chronic kidney diseases. Minerva Med. 2013; 104 (1): 23–30. PMID: 23392535.

[22] Tsikas D. Assessment of lipid peroxidation by measuring malondialdehyde (MDA) and relatives in biological samples: Analytical and biological challenges. Ann. Biochem. 2017; 524: 13–30. DOI: 10.1016/j.ab.2016.10.021.

[23] Chistyakov V.A. Nonspecific mechanisms of protection against the destructive action of reactive oxygen species. Uspekhi sovremennoy biologii. 2008; 128 (3): 300–306. (In Russ.)

[24] Чистяков В.А. Неспецифические механизмы защиты от деструктивного действия активных форм кислорода. Успехи соврем. биол. 2008; 128 (3): 300–306.

[25] Kozina L.S., Stvolinsky S.L., Fedorova T.N., Bulygina E.R., Arzumanyan E.S., Arutyunyan A.V., Khavinson V.Kh. Study of antioxidant and membraneprotective properties of short peptides in mo­del experiments. Voprosy biologicheskoj, medicinskoj i farmacevticheskoj himii. 2008; (6): 31–36. (In Russ.)

[26] Козина Л.С., Стволинский С.Л., Фёдорова Т.Н., Булыгина Е.Р., Арзуманян Е.С., Арутюнян А.В., Хавинсон В.Х. Изучение антиоксидантных и мембранопротекторных свойств коротких пептидов в модельных экспериментах. Вопр. биол., мед. и фармацевтич. химии. 2008; (6): 31–36.

RIGHTS & PERMISSIONS

Zharikov A.Y., Mazko O.N., Makarova O.G., Bobrov I.P., Kalnitsky A.S., Zharikova G.V., Yakushev N.N., Gossen I.E.